MiR-520h Stimulates Drug Resistance to Paclitaxel by Targeting the OTUD3-PTEN Axis in Breast Cancer

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2020 Aug 11

PMID 32775453

Citations 12

Authors

Wenwen Geng

Haiyun Song

Qianqian Zhao

Ke Dong

Qian Pu

Haidong Gao

Yanrong Lv

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) have been identified as negative posttranscriptional regulators of target genes and are involved directly in the pathological processes of tumors, including drug resistance. However, the exact function of miR-520h in breast cancer remains poorly understood. The aim of this study was to investigate the molecular mechanisms of miR-520h in paclitaxel resistance in the MCF-7 breast cancer cell line. Ectopic expression of miR-520h could promote the proliferation of breast cancer cells and inhibit paclitaxel-induced cell apoptosis. Inhibiting the expression of miR-520h could enhance the sensitivity to paclitaxel in paclitaxel-resistant MCF-7/Taxol cells. Furthermore, luciferase reporter assays showed that OTUD3 was a direct target of miR-520h. OTUD3 plays a necessary role in the paclitaxel resistance effect of miR-520h, and cotreatment with a miR-520h inhibitor and OTUD3 overexpression significantly enhanced MCF-7 cell sensitivity to paclitaxel. Moreover, miR-520h substantially inhibited the protein expression of PTEN via OTUD3 and subsequently affected downstream p-AKT pathway activity. In a clinical study, we also found that high miR-520h expression was associated with more aggressive pathological characteristic and poor prognosis. Therefore, our findings showed that miR-520h targeted the OTUD3-PTEN axis to drive paclitaxel resistance, and this miR might be an important potential target for breast cancer treatment.

Citing Articles

Research progress in deubiquitinase OTUD3.

Hou D, Yu D, Yang G, Hu Y, Li H Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025; 49(8):1341-1352.

PMID: 39788523 PMC: 11628234. DOI: 10.11817/j.issn.1672-7347.2024.230581.

Identification of chemoresistance associated key genes-miRNAs-TFs in docetaxel resistant breast cancer by bioinformatics analysis.

Raju B, Narendra G, Verma H, Silakari O 3 Biotech. 2024; 14(5):128.

PMID: 38590544 PMC: 10998825. DOI: 10.1007/s13205-024-03971-2.

OTUD3 suppresses the mTORC1 signaling by deubiquitinating KPTN.

Li J, Yang D, Lin Y, Xu W, Zhao S, Wang C Front Pharmacol. 2024; 14:1337732.

PMID: 38288086 PMC: 10822905. DOI: 10.3389/fphar.2023.1337732.

Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7.

Apollonova V, Plevako D, Garanin A, Sidina E, Zabegina L, Knyazeva M Cancer Drug Resist. 2023; 6(3):596-610.

PMID: 37842231 PMC: 10571055. DOI: 10.20517/cdr.2023.19.

Deubiquitinase OTUD3: a double-edged sword in immunity and disease.

Xu Q, He L, Zhang S, Di X, Jiang H Front Cell Dev Biol. 2023; 11:1237530.

PMID: 37829187 PMC: 10566363. DOI: 10.3389/fcell.2023.1237530.

References

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

Xu H, Sun J, Shi C, Sun C, Yu L, Wen Y . miR-29s inhibit the malignant behavior of U87MG glioblastoma cell line by targeting DNMT3A and 3B. Neurosci Lett. 2015; 590:40-6. DOI: 10.1016/j.neulet.2015.01.060. View

Liang Z, Feng Q, Xu L, Li S, Zhou L . CREPT regulated by miR-138 promotes breast cancer progression. Biochem Biophys Res Commun. 2017; 493(1):263-269. DOI: 10.1016/j.bbrc.2017.09.033. View

Su C, Wang M, Hong C, Chen H, Su Y, Wu C . miR-520h is crucial for DAPK2 regulation and breast cancer progression. Oncogene. 2015; 35(9):1134-42. DOI: 10.1038/onc.2015.168. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

Rauhut R, Lendeckel W, Tuschl T . Identification of novel genes coding for small expressed RNAs. Science. 2001; 294(5543):853-8. DOI: 10.1126/science.1064921. View

Ebert M, Sharp P . Roles for microRNAs in conferring robustness to biological processes. Cell. 2012; 149(3):515-24. PMC: 3351105. DOI: 10.1016/j.cell.2012.04.005. View

Marcotte R, Sayad A, Brown K, Sanchez-Garcia F, Reimand J, Haider M . Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell. 2016; 164(1-2):293-309. PMC: 4724865. DOI: 10.1016/j.cell.2015.11.062. View

Yuan X, Ma R, Yang S, Jiang L, Wang Z, Zhu Z . miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1. Cell Cycle. 2019; 18(14):1660-1669. PMC: 6619958. DOI: 10.1080/15384101.2019.1632138. View

10.

Xie F, Hosany S, Zhong S, Jiang Y, Zhang F, Lin L . MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1. PLoS One. 2017; 12(10):e0185565. PMC: 5634539. DOI: 10.1371/journal.pone.0185565. View

11.

Wang W, Zhang L, Wang Y, Ding Y, Chen T, Wang Y . Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Cell Death Dis. 2017; 8(10):e3071. PMC: 5680582. DOI: 10.1038/cddis.2017.460. View

12.

Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R, Izzotti A . Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res. 2017; 7(6):1350-1371. PMC: 5489783. View

13.

Shen Q, Yao Q, Sun J, Feng L, Lu H, Ma Y . Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin. FEBS Lett. 2013; 588(1):184-91. DOI: 10.1016/j.febslet.2013.11.034. View

14.

Liu X, Tang H, Chen J, Song C, Yang L, Liu P . MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget. 2015; 6(24):20070-83. PMC: 4652988. DOI: 10.18632/oncotarget.4039. View

15.

Su J, Chen P, Chen Y, Chen S, Chang Y, Jan Y . Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res. 2010; 70(12):5096-108. PMC: 2891368. DOI: 10.1158/0008-5472.CAN-09-4148. View

16.

Sarkar F, Li Y, Wang Z, Kong D, Ali S . Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 2010; 13(3):57-66. PMC: 2883024. DOI: 10.1016/j.drup.2010.02.001. View

17.

Hassan M, Ansari J, Spooner D, Hussain S . Chemotherapy for breast cancer (Review). Oncol Rep. 2010; 24(5):1121-31. DOI: 10.3892/or_00000963. View

18.

van Schooneveld E, Wildiers H, Vergote I, Vermeulen P, Dirix L, Van Laere S . Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015; 17:21. PMC: 4332424. DOI: 10.1186/s13058-015-0526-y. View

19.

Zhang B, Zhao R, He Y, Fu X, Fu L, Zhu Z . MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. Oncotarget. 2016; 7(5):5702-14. PMC: 4868715. DOI: 10.18632/oncotarget.6790. View

20.

Song M, Salmena L, Pandolfi P . The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13(5):283-96. DOI: 10.1038/nrm3330. View